|
Category:pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Appearance: | white fine powder (est) |
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 213.00 °C. @ 760.00 mm Hg (est)
|
| Boiling Point: | 957.12 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 991.00 °F. TCC ( 532.60 °C. ) (est)
|
| logP (o/w): | 3.950 (est) |
| Soluble in: |
| | water, 0.004847 mg/L @ 25 °C (est) |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intravenous-dog LDLo 15 mg/kg
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
BEHAVIORAL: ATAXIA
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION
National Technical Information Service. Vol. PB83-170969
intraperitoneal-mouse LD50 128 mg/kg
SKIN AND APPENDAGES (SKIN): HAIR: OTHER
National Technical Information Service. Vol. PB83-170969
intravenous-mouse LD50 12 mg/kg
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
BEHAVIORAL: ATAXIA
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Pharmaceutical Research. Vol. 4, Pg. 162, 1987.
intraperitoneal-rat LD50 32530 ug/kg
LUNGS, THORAX, OR RESPIRATION: DYSPNEA
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
National Technical Information Service. Vol. PB83-170969
intravenous-rat LDLo 85 mg/kg
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE
Journal of Toxicological Sciences. Vol. 19(Suppl
|
| Dermal Toxicity: |
|
Not determined
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | pharmaceuticals / chemical synthisis |
| Recommendation for paclitaxel usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for paclitaxel flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
Other Information:
| (IUPAC): | Atomic Weights of the Elements 2011 (pdf) |
| Videos: | The Periodic Table of Videos |
| tgsc: | Atomic Weights use for this web site |
| (IUPAC): | Periodic Table of the Elements |
| CHEBI: | View |
| CHEMBL: | View |
| KEGG (GenomeNet): | D00491 |
| HMDB (The Human Metabolome Database): | Search |
| Export Tariff Code: | 2932.90.4100 |
| MedlinePlusSupp: | View |
| VCF-Online: | VCF Volatile Compounds in Food |
| ChemSpider: | View |
| Wikipedia: | View |
Formulations/Preparations:
•parenteral: for injection, concentrate, for iv infusion: 6 mgml onxol (with dehydrated alcohol 49.7% (vv) and polyoxyl 35 castor oil 527 mgml) (teva), paclitaxel injection (with dehydrated alcohol 49.7% (vv) and polyoxyl 35 castor oil 527 mgml) (bedford, mayne, udl), taxol (with dehydrated alcohol 49.7% (vv) and polyoxyl 35 castor oil 527 mgml) (bristol-myers squibb).
•parenteral: for injectable suspension, for iv infusion: 100 mg (of paclitaxel) abraxane (abraxis). paclitaxel (albumin-bound)
•paclitaxel is commercially available as protein-bound particles consisting of paclitaxel bound to albumin; the mean particle size of albumin-bound paclitaxel is about 130 nm. albumin-bound paclitaxel is a sterile, white to yellow lyophilized powder that must be reconstituted for use as an injectable suspension; there are no solvents. each single-use vial contains 100 mg of paclitaxel and approximately 900 mg of human albumin.
•because paclitaxel is extremely hydrophobic, the commercially available injection concentrate is a sterile, nonaqueous solution of the drug in polyoxyl 35 castor oil (cremophor el, polyoxyethylated castor oil) and dehydrated alcohol. commercially available paclitaxel for injection concentrate is a clear, colorless to slightly yellow, viscous solution. following dilution of paclitaxel for injection concentrate with 5% dextrose and 0.9% sodium chloride injection or 5% dextrose and ringer's injection, solutions containing 0.6 or 1.2 mg of paclitaxel per ml maintain a ph of 4.4-5.6 for up to 27 hours.
|
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| | abraxane | | (2a,5b,7b,10b,13a)-4,10-bis( | acetyloxy)-13-{[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate | | | anzatax | | | cyclopax | | | ebetaxel | | 5b,20- | epoxy-1,2a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-Diacetate 2-Benzoate 13-Ester with (2R,3S)-N-Benzoyl-3-phenylisoserine | | | genetaxyl | | | genexol | | | intaxel | | | mitotax | | | peclitaxel | | | taxol | | | yewtaxan |
Articles:
| Info:Taxol |
| PubMed:Safety and Effectiveness of Bevacizumab-Containing Treatment for Non-Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study. |
| PubMed:Editorial: plant natural products: inspiring sources for drugs development. |
| PubMed:PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy. |
| PubMed:Constitutive androstane receptor ligands modulate the anti-tumor efficacy of paclitaxel in non-small cell lung cancer cells. |
| PubMed:Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. |
| PubMed:Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. |
| PubMed:The Development and Maintenance of Paclitaxel-induced Neuropathic Pain Require Activation of the Sphingosine 1-Phosphate Receptor Subtype 1. |
| PubMed:Rapid assessment of drug response in cancer cells using microwell array and molecular imaging. |
| PubMed:Improvement of hairy root cultures and plants by changing biosynthetic pathways leading to pharmaceutical metabolites: Strategies and applications. |
| PubMed:Systemic toxicity induced by paclitaxel in vivo is associated with the solvent cremophor EL through oxidative stress-driven mechanisms. |
| PubMed:Antiproliferative and immunostimulatory activity of a protein from Pleurotus eryngii. |
| PubMed:Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience. |
| PubMed:Modulation of estrogen and epidermal growth factor receptors by rosemary extract in breast cancer cells. |
| PubMed:The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials. |
| PubMed:Metabolic engineering approaches for production of biochemicals in food and medicinal plants. |
| PubMed:A Targeting Drug Delivery System for Ovarian Carcinoma: Transferrin Modified Lipid Coated Paclitaxel-loaded Nanoparticles. |
| PubMed:Bioproduction of baccatin III, an advanced precursor of paclitaxol, with transgenic Flammulina velutipes expressing the 10-deacetylbaccatin III-10-O-acetyl transferase gene. |
| PubMed:Experimentation with inhaled bronchodilators and corticosteroids. |
| PubMed:U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. |
| PubMed:Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. |
| PubMed:Stent thrombosis with drug-eluting stents: is the paradigm shifting? |
| PubMed:Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS. |
| PubMed:The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). |
| PubMed:Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials. |
| PubMed:Exploring a natural MDR reversal agent: potential of medicinal food supplement Nerium oleander leaf distillate. |
| PubMed:Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation. |
| PubMed:Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells. |
| PubMed:Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. |
| PubMed:Randomized trial of Legflow(®) paclitaxel eluting balloon and stenting versus standard percutaneous transluminal angioplasty and stenting for the treatment of intermediate and long lesions of the superficial femoral artery (RAPID trial): study protocol for a randomized controlled trial. |
| PubMed:Synergistic effect of a novel cyclic pentadepsipeptide, neoN-methylsansalvamide, and paclitaxel on human multidrug resistance cancer cell lines. |
| PubMed:Dynamic cost-effectiveness of oncology drugs. |
| PubMed:Update on taxane development: new analogs and new formulations. |
| PubMed:Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. |
| PubMed:Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience. |
| PubMed:Metastatic melanoma - a review of current and future drugs. |
| PubMed:Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts. |
| PubMed:Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. |
| PubMed:The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. |
| PubMed:Overview of the 2011 food and drug administration's circulatory system devices panel of the medical devices advisory committee meeting on the Zilver® PTX® drug-eluting peripheral stent. |
| PubMed:Determination of morphine, codeine, and paclitaxel in human serum and plasma by micellar electrokinetic chromatography. |
| PubMed:Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies. |
| PubMed:The effects of selenium on tumor growth in epithelial ovarian carcinoma. |
| PubMed:Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway. |
| PubMed:Cell-type dependent response of melanoma cells to aloe emodin. |
| PubMed:The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy. |
| PubMed:Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. |
| PubMed:Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy. |
| PubMed:Self-assembly and paclitaxel loading capacity of cellulose-graft-poly(lactide) nanomicelles. |
| PubMed:Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. |
| PubMed:Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. |
| PubMed:Ipilimumab: its potential in non-small cell lung cancer. |
| PubMed:Direct and fast determination of paclitaxel, morphine and codeine in urine by micellar electrokinetic chromatography. |
| PubMed:A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. |
| PubMed:Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. |
| PubMed:Anti-proliferative activity and suppression of P-glycoprotein by (-)-antofine, a natural phenanthroindolizidine alkaloid, in paclitaxel-resistant human lung cancer cells. |
| PubMed:Bevacizumab in the treatment of metastatic breast cancer: friend or foe? |
| PubMed:New anti-cancer characteristics of jatrophane diterpenes from Euphorbia dendroides. |
| PubMed:Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. |
| PubMed:Drug-eluting Stents in Acute Coronary Syndrome: Is There a Risk of Stent Thrombosis with Second-Generation Stents? |
| PubMed:Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. |
| PubMed:Dairy milk fat augments paclitaxel therapy to suppress tumour metastasis in mice, and protects against the side-effects of chemotherapy. |
| PubMed:Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. |
| PubMed:Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. |
| PubMed:Gossypol decreases tumor necrosis factor-α-induced intercellular adhesion molecule-1 expression via suppression of NF-κB activity. |
| PubMed:Plant-derived bioactive compounds produced by endophytic fungi. |
| PubMed:Clinical studies with sirolimus, zotarolimus, everolimus, and biolimus A9 drug-eluting stent systems. |
| PubMed:18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. |
| PubMed:The flavonoid quercetin transiently inhibits the activity of taxol and nocodazole through interference with the cell cycle. |
| PubMed:Evaluation of the genotoxicity of cisplatin, paclitaxel and 5-fluorouracil combined treatment in the Drosophila wing-spot test. |
| PubMed:Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. |
| PubMed:Reporting of studies on new medicines in major medical journals: a case study in breast cancer. |
| PubMed:Osthole suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt/mTOR pathway. |
| PubMed:Investigational new drug-directed, 5-day repeat dose toxicity study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) administered with or without Taxol in Sprague-Dawley rats. |
| PubMed:Clinically relevant anticancer polymer Paclitaxel therapeutics. |
| PubMed:Beyond the black box: drug- and device-associated hypersensitivity events. |
| PubMed:Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope. |
| PubMed:[A case of advanced gastric cancer that a medical therapy effect was provided grade 3 by a histopathological diagnosis after long-term chemotherapy]. |
| PubMed:Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. |
| PubMed:Development and validation of a stability-indicating method for the quantitation of Paclitaxel in pharmaceutical dosage forms. |
| PubMed:Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes. |
| PubMed:Ovarian cancer (advanced). |
| PubMed:[Acceptable safety of bevacizumab therapy in combination with chemotherapy in patients with advanced lung cancer.]. |
| PubMed:Symptom management in patients with cancer of the female reproductive system receiving chemotherapy. |
| PubMed:The mouse lymphoma assay detects recombination, deletion, and aneuploidy. |
| PubMed:Analysis of cell cycle phases and proliferative capacity in mice bearing melanoma maintained on different dietary proteins. |
| PubMed:Discovery of ixabepilone. |
| PubMed:IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. |
| PubMed:Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the Xience V Everolimus-Eluting Coronary Stent. |
| PubMed:Evolution of bevacizumab-based therapy in the management of breast cancer. |
| PubMed:Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. |
| PubMed:Endothelial cell recovery between comparator polymer-based drug-eluting stents. |
| PubMed:A three-year survivor case of gastric cancer with peritoneal dissemination--an outpatient with second-line weekly paclitaxel. |
| PubMed:Coronary artery stents: Part I. Evolution of percutaneous coronary intervention. |
| PubMed:Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. |
| PubMed:Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183. |
| PubMed:Epothilones: clinical update and future directions. |
| PubMed:Cordyceps sinensis health supplement enhances recovery from taxol-induced leukopenia. |
| PubMed:[Drug-eluting stent thrombosis and its pharmacological prevention]. |
| PubMed:Taxanes from Shells and Leaves of Corylus avellana. |
| PubMed:Transformation of bioactive compounds by Fusarium sacchari fungus isolated from the soil-cultivated ginseng. |
| PubMed:Effect of the bioactive metabolite euplotin C on phagocytosis and fluid-phase endocytosis in the single-celled eukaryote Paramecium. |
| PubMed:Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. |
| PubMed:Litchi flavonoids: isolation, identification and biological activity. |
| PubMed:FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. |
| PubMed:Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. |
| PubMed:Pathology of drug-eluting stents: implications for coronary intervention. |
| PubMed:Unanswered questions--drug-eluting stents and the risk of late thrombosis. |
| PubMed:New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. |
| PubMed:Second-line treatment of small-cell lung cancer. |
| PubMed:Immunomodulatory and anticancer activities of flavonoids extracted from litchi (Litchi chinensis Sonn) pericarp. |
| PubMed:A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics: expression, purification, and characterization. |
| PubMed:[Successful treatment of an elderly patient with advanced gastric cancer using low-doses of 5-fluorouracil, levofolinate calcium, and cis-platinum with chronomodulation]. |
| PubMed:Evaluation of paclitaxel rearrangement involving opening of the oxetane ring and migration of acetyl and benzoyl groups. |
| PubMed:Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer. |
| PubMed:Off-label use: an industry perspective on expanding use beyond approved indications. |
| PubMed:Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents. |
| PubMed:The role of capecitabine in first-line treatment for patients with metastatic breast cancer. |
| PubMed:Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice. |
| PubMed:Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. |
| PubMed:Large-scale purification of 13-dehydroxybaccatin III and 10-deacetylpaclitaxel, semi-synthetic precursors of paclitaxel, from cell cultures of Taxus chinensis. |
| PubMed:Determination of docetaxel and Paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies. |
| PubMed:Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. |
| PubMed:Impact of a scientific presentation on community treatment patterns for primary breast cancer. |
| PubMed:Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. |
| PubMed:[A case of recurrent gastric cancer with peritoneal dissemination successfully treated over 1 year 8 months with combined chemotherapy of paclitaxel and TS-1]. |
| PubMed:Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux. |
| PubMed:Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. |
| PubMed:Second- and third-line treatments in non-small cell lung cancer. |
| PubMed:Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. |
| PubMed:Topotecan: weighing in when there are many options. |
| PubMed:Bypassing Bypass Surgery and Other Success Stories from the National Institutes of Health. |
| PubMed:The World Health Organization's prequalification program and its potential effect on data exclusivity laws. |
| PubMed:Docetaxel in the management of ovarian cancer. |
| PubMed:A sesquiterpenelactone from Inula britannica induces anti-tumor effects dependent on Bcl-2 phosphorylation. |
| PubMed:Cardiovascular device development: drug-eluting stents and implantable devices for the treatment of heart failure--the view from the Circulatory System Advisory Panel. |
| PubMed:Capecitabine: a review. |
| PubMed:Development of docetaxel in advanced non-small-cell lung cancer. |
| PubMed:Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. |
| PubMed:Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. |
| PubMed:Problems with drug-eluting coronary stents--the FDA perspective. |
| PubMed:Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. |
| PubMed:FDA approves Taxus stent; materials managers cheer. |
| PubMed:United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. |
| PubMed:Patent infringement. Court denies motion to alter patent claim decision. |
| PubMed:New agents in the treatment of small-cell lung cancer: focus on gemcitabine. |
| PubMed:Combined effects of resveratrol and paclitaxel on lung cancer cells. |
| PubMed:Drug-eluting stents substantially lower rate of restenosis. |
| PubMed:FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. |
| PubMed:Weekly paclitaxel for a patient with advanced gastric cancer. |
| PubMed:Current therapies in ovarian cancer. |
| PubMed:Antiproliferative activity of apples is not due to phenolic-induced hydrogen peroxide formation. |
| PubMed:Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. |
| PubMed:Campylobacter fetus adheres to and enters INT 407 cells. |
| PubMed:A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. |
| PubMed:From taxol to Taxol: the changing identities and ownership of an anti-cancer drug. |
| PubMed:Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. |
| PubMed:Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations. |
| PubMed:Recent advances in the treatment of AIDS-related Kaposi's sarcoma. |
| PubMed:Trastuzumab/chemotherapy combinations in metastatic breast cancer. |
| PubMed:Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy. |
| PubMed:New drugs in gynecologic cancer. |
| PubMed:HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer. |
| PubMed:The effect of paclitaxel on gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cells. |
| PubMed:The effect of paclitaxel on 2-aminofluorene-DNA adducts formation and arylamine N-acetyltransferase activity and gene expression in human lung tumor cells (A549). |
| PubMed:FDA: approval of generic drug reversed by U.S. Court of Appeals. |
| PubMed:Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. |
| PubMed:Monte Carlo docking simulations of cyclomaltoheptaose and dimethyl cyclomaltoheptaose with paclitaxel. |
| PubMed:Drug combination approved for advanced breast cancer. |
| PubMed:Inhibitory effect of tumor cell proliferation and induction of G2/M cell cycle arrest by panaxytriol. |
| PubMed:Novel polyphenol molecule isolated from licorice root (Glycrrhiza glabra) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. |
| PubMed:From the Food and Drug Administration. |
| PubMed:What ever happened to...? Looking back 10 years. |
| PubMed:A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. |
| PubMed:Paclitaxel for treating KS. |
| PubMed:Low-dose paclitaxel effective in advanced KS. |
| PubMed:Inter-species differences in drug properties. |
| PubMed:Clinical pharmacokinetics of capecitabine. |
| PubMed:Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. |
| PubMed:Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. |
| PubMed:Nanospheres of biodegradable polymers: a system for clinical administration of an anticancer drug paclitaxel (Taxol). |
| PubMed:New therapies for the treatment of AIDS-related Kaposi sarcoma. |
| PubMed:[Evidenced-based medicine and future direction of Taxol]. |
| PubMed:Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. |
| PubMed:Chemotherapy for advanced hormone refractory prostate cancer. |
| PubMed:Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. |
| PubMed:The mycotoxin patulin induces intra- and intermolecular protein crosslinks in vitro involving cysteine, lysine, and histidine side chains, and alpha-amino groups. |
| PubMed:FDA advisors recommend approval of taxol for node-positive breast cancer. |
| PubMed:Cancer chemotherapy, biodiversity, public and private property: the case of the anti-cancer drug taxol. |
| PubMed:Fluoropyrimidines: a critical evaluation. |
| PubMed:Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. |
| PubMed:Treatment of refractory and recurrent ovarian cancer. |
| PubMed:Tour de paclitaxel: biocatalysis for semisynthesis. |
| PubMed:Oral 5-FU analogues in the treatment of breast cancer. |
| PubMed:Clinical status and optimal use of topotecan. |
| PubMed:Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole. |
| PubMed:Colchicine down-regulates lipopolysaccharide-induced granulocyte-macrophage colony-stimulating factor production in murine macrophages. |
| PubMed:Docetaxel and gemcitabine released for cancer chemotherapy. |
| PubMed:Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy. |
| PubMed:Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. |
| PubMed:A preliminary risk-benefit assessment of paclitaxel. |
| PubMed:USA update on paclitaxel in ovarian cancer. |
| PubMed:Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. |
| PubMed:Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. |
| PubMed:[Reproductive and developmental toxicity studies of paclitaxel. (III)--Intravenous administration to rats during the perinatal and lactation periods]. |
| PubMed:[Reproductive and developmental toxicity studies of paclitaxel. (II)--Intravenous administration to rats during the fetal organogenesis]. |
| PubMed:[Reproductive and developmental toxicity studies of paclitaxel. (I)--Intravenous administration to rats prior to and in the early stages of pregnancy]. |
| PubMed:[Toxicity studies of paclitaxel. (II)--One-month intermittent intravenous toxicity in rats]. |
| PubMed:Taxol induces the hematopoietic growth factor granulocyte-macrophage colony-stimulating factor in murine B-cells by stabilization of granulocyte-macrophage colony-stimulating factor nuclear RNA. |
| PubMed:Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. |
| PubMed:New therapeutic agents marketed in 1993. |
| PubMed:From the Food and Drug Administration. |
| PubMed:Patient care issues: the management of paclitaxel-related toxicities. |
| PubMed:Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of taxol. |
| PubMed:Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat. |
| PubMed:Nursing implications in the administration of paclitaxel (TAXOL). |
| PubMed:Clinical development of Taxol. |
| PubMed:Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. |
| PubMed:FDA approves treatment IND protocol for taxol. |
| PubMed:From the Food and Drug Administration. |
| PubMed:Drugs affecting microtubule dynamics increase alpha-tubulin mRNA accumulation via transcription in Tetrahymena thermophila. |
|
a cyclodecane isolated from the bark of the pacific yew tree, taxus brevifolia. it stabilizes microtubules in their polymerized form leading to cell death.nci: a compound extracted from the pacific yew tree taxus brevifolia with antineoplastic activity. paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. this agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein bcl-2 (b-cell leukemia 2). nci thesaurus)
|
3D/inchi